{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:24:05Z","timestamp":1786973045753,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114196","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T11:58:30Z","timestamp":1719662310000},"page":"114196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Multicenter phase I\/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer"],"prefix":"10.1016","volume":"207","author":[{"given":"Tiziana","family":"Pressiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Balsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Noventa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daris","family":"Ferrrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Soto","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sold\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zecchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Domenico","family":"Rizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2024.114196_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"10272","key":"10.1016\/j.ejca.2024.114196_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2024.114196_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ejca.2024.114196_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"14","key":"10.1016\/j.ejca.2024.114196_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2024.114196_bib6","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114196_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"10.1016\/j.ejca.2024.114196_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114196_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.ejca.2024.114196_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"suppl_7","key":"10.1016\/j.ejca.2024.114196_bib11","article-title":"Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114196_bib12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"issue":"10391","key":"10.1016\/j.ejca.2024.114196_bib13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2024.114196_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2024.114196_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100910","article-title":"Genomics driven precision oncology in advanced biliary tract cancer improves survival","volume":"42","author":"Kumar-Sinha","year":"2023","journal-title":"Neoplasia"},{"issue":"18","key":"10.1016\/j.ejca.2024.114196_bib16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.114196_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejca.2024.114196_bib18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","article-title":"Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial","volume":"4","author":"Sahai","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114196_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2024.114196_bib20","doi-asserted-by":"crossref","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114196_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114196_bib23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114196_bib24","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post Hoc Analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.114196_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1387","article-title":"Advanced extrahepatic cholangiocarcinoma: post Hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"Volume 34","author":"Lamarca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114196_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.963753","article-title":"Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials","volume":"12","author":"Ledenko","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114196_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","article-title":"A phase II\/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study","volume":"24","author":"Niger","year":"2024","journal-title":"BMC Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:24:34Z","timestamp":1786969474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"alternative-id":["S0959804924008529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114196","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter phase I\/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114196"}}